Public, NASDAQ:PGLA
NASDAQ Capital Market
MethylGene, Progen Shares Dive on Study Problems
Date: Thu, 24 Jul 2008 01:06:32 GMT
Tags:
MethylGene, Progen Shares Dive on Study Problems
Therapeutics Daily (subscription) (press release) - Jul 24, 2008
Therapeutics Daily (subscription) (press release) - Jul 24, 2008
Shares of Montreal - based MethylGene Inc . plummeted 45 percent Wednesday on the news that the firm was suspending enrollment of new patients in clinical trials of its experimental cancer compound ...
Unusual 11 Mid-Day Movers 7/23: PHLY, FED, COBR, RDN Higher; PGLA, PFBC, AEHR, ANAD Lower
Date: Wed, 23 Jul 2008 17:02:04 GMT
Tags:
Unusual 11 Mid-Day Movers 7/23: PHLY, FED, COBR, RDN Higher; PGLA, PFBC, AEHR, ANAD Lower
StreetInsider.com (subscription) - Jul 23, 2008
StreetInsider.com (subscription) - Jul 23, 2008
Philadelphia Consolidated Holding Corp . ( Nasdaq : PHLY ) 63.2 % HIGHER ; Tokio Marine Holdings , Inc . and Philadelphia Consolidated entered into a definitive agreement under which TMHD will ...
Market Report -- In Play (WIRES)
Date: Wed, 23 Jul 2008 06:29:15 GMT
Tags:
Market Report -- In Play (WIRES)
MSN Money - Jul 23, 2008
MSN Money - Jul 23, 2008
On The Wires Board of Progen Pharmaceuticals ( PGLA ) announces that it had discontinued the PI - 88 ph . 3 study in liver cancer ; co confirms its strategic direction to develop its existing ...
Aussie stocks rise over 2 pct; Progen slumps
Date: Wed, 23 Jul 2008 03:23:55 GMT
Tags:
Aussie stocks rise over 2 pct; Progen slumps
Ninemsn - Jul 23, 2008
Ninemsn - Jul 23, 2008
SYDNEY , July 23 ( Reuters ) - Australian shares rose 2.2 percent to a three - week high on Wednesday as a drop in oil prices bolstered investor sentiment , lifting consumer - related firms and ...
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
Date: Wed, 23 Jul 2008 00:44:35 GMT
Tags:
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
MarketWatch - Jul 23, 2008
Progen Pharma Shares Plunge After Drug Trial Ended (Update1) - Bloomberg
Bloomberg - Trading Markets (press release) - Australian Life Scientist
MarketWatch - Jul 23, 2008
, , ) today announced that it had discontinued the PI - 88 phase 3 study in liver cancer.Progen confirmed its strategic direction to develop its existing portfolio of compounds and the company ...
Progen Pharma Shares Plunge After Ending Drug Trial (Update2) - BloombergProgen Pharma Shares Plunge After Drug Trial Ended (Update1) - Bloomberg
Bloomberg - Trading Markets (press release) - Australian Life Scientist
Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A (PR Newswire)
Date: Wed, 23 Jul 2008 00:35:00 Etc/GMT
Tags:
Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited today announced that it had discontinued the PI-88 phase 3 study in liver cancer.
Presentation of Data on Progen's Cancer Epigenetic Targets Platform (PR Newswire)
Date: Fri, 30 May 2008 05:52:00 Etc/GMT
Tags:
ASX: PGL - News; Nasdaq: PGLA - News) New data on Progen's cancer epigenetic targets program will be presented tomorrow at the American Association for Cancer Research Epigenetics Meeting in Boston by Progen's collaborators at the Johns Hopkins University.
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 (PR Newswire)
Date: Thu, 15 May 2008 01:16:00 Etc/GMT
Tags:
Progen Pharmaceuticals Limited today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 for patients with advanced cancer.
PROGEN PHARMACEUTICALS LTD Financials (EDGAR Online Financials)
Date: Sat, 22 Dec 2007 14:04:29 Etc/GMT
Tags: